Peptic Ulcer - Pipeline Insight, 2021

DelveInsights, Peptic Ulcer - Pipeline Insight, 2021, report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Peptic Ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Peptic Ulcer Understanding
Peptic Ulcer: Overview
A peptic ulcer is an open sore or raw area in the lining of the stomach or intestine. There are two types of peptic ulcers: Gastric ulcer -- occurs in the stomach and Duodenal ulcer -- occurs in the first part of the small intestine. Normally, the lining of the stomach and small intestines can protect itself against strong stomach acids. Most ulcers occur in the first layer of the inner lining. A hole in the stomach or duodenum is called a perforation. This is a medical emergency. The most common cause of ulcers is infection of the stomach by bacteria called Helicobacter pylori (H pylori). Most people with peptic ulcers have these bacteria living in their digestive tract. Yet, many people who have these bacteria in their stomach do not develop an ulcer.

"Peptic Ulcer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peptic Ulcer pipeline landscape is provided which includes the disease overview and Peptic Ulcer treatment guidelines. The assessment part of the report embraces, in depth Peptic Ulcer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peptic Ulcer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Peptic Ulcer R&D. The therapies under development are focused on novel approaches to treat/improve Peptic Ulcer.

Peptic Ulcer Emerging Drugs Chapters
This segment of the Peptic Ulcer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peptic Ulcer Emerging Drugs
Fexuprazan: Daewoong Pharmaceutical
Fexuprazan is a novel potassium-competitive acid blocker (P-CAB) developed by Daewoong, which reversibly blocks the proton pump that secretes gastric acids located in the cannalicular membrane. It is a next-generation of proton pump inhibitors (PPI), which are widely used for gastroesophageal reflux disease (GERD). The drug is currently in phase III stage of clinical trial evaluation to treat peptic ulcers.

KFP-H008: Jiangsu Carephar pharmaceuticals
KFP-H008 is a Potassium-competitive acid blocker being developed by Jiangsu Carephar pharmaceuticals. Currently, it is in Phase III stage of clinical trial evaluation to treat Duodenal ulcer.
Further product details are provided in the report..

Peptic Ulcer: Therapeutic Assessment
This segment of the report provides insights about the different Peptic Ulcer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Peptic Ulcer
There are approx. 8+ key companies which are developing the therapies for Peptic Ulcer. The companies which have their Peptic Ulcer drug candidates in the most advanced stage, i.e. phase III include, Daewoong Pharmaceutical.

Phases
DelveInsights report covers around 8+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Peptic Ulcer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peptic Ulcer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peptic Ulcer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peptic Ulcer drugs.

Peptic Ulcer Report Insights
Peptic Ulcer Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Peptic Ulcer Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Peptic Ulcer drugs?
How many Peptic Ulcer drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peptic Ulcer?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Peptic Ulcer therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Peptic Ulcer and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Daewoong Pharmaceutical
HK inno.N Corporation
PharmaKing
Recce Pharmaceuticals
Sequella Inc
Shandong Luoxin Pharmaceutical
RaQualia Pharma
Sihuan Pharmaceutical Holdings Group
Sinil Pharmaceutical

Key Products
Fexuprazan
Tegoprazan
PMK S005
R435
SQ109
Anaprazole
SI-001002

Introduction
Executive Summary
Peptic Ulcer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Peptic Ulcer DelveInsights Analytical Perspective
In-depth Commercial Assessment
Peptic Ulcer companies collaborations, Licensing, Acquisition -Deal Value Trends
Peptic Ulcer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Fexuprazan: Daewoong Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
PMK S005: PharmaKing
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
KFP H009: Jiangsu Carephar Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..

Inactive Products
Comparative Analysis
Peptic Ulcer Key Companies
Peptic Ulcer Key Products
Peptic Ulcer- Unmet Needs
Peptic Ulcer- Market Drivers and Barriers
Peptic Ulcer- Future Perspectives and Conclusion
Peptic Ulcer Analyst Views
Peptic Ulcer Key Companies
Appendix

List Of Tables

Table 1 Total Products for Peptic Ulcer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Peptic Ulcer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available